Eizen Joshua M 4

What Happened

• Joshua M. Eizen, AN2 Therapeutics’ Chief Operating Officer and Chief Legal Officer, was granted a total of 150,000 shares on February 20, 2026. The filing shows two award entries: 50,000 shares reported as a grant (common stock/RSUs) and 100,000 reported as a derivative award (RSUs). All were issued at $0.00 (no cash paid).

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (appears timely).
• Consideration: $0.00 per share (awarded RSUs, not an open-market purchase).
• Vesting highlights:
  • 50,000 RSUs: vest 1/4 annually over four years starting January 1, 2026 (F1).
  • Existing and additional RSU balances (from filing footnotes) include various tranches totaling prior RSUs with staggered vesting dates from 2024–2026 (F2).
  • Options referenced vest monthly over four years from January 1, 2026 (F4).
• Other notes: Filing references a prior purchase of 5,000 shares under the 2022 ESPP (F3).
• Shares owned after the reported grant are not specified in the summary provided.

Context

• These entries are awards of restricted stock units (RSUs), a form of deferred equity compensation. RSUs vest over time and only convert to tradable shares if Eizen remains in service through each vesting date. Awards at $0 are common for executive compensation and do not represent an open-market purchase signal.